Long-term outcome and predictors of long-term disease activity in Natalizumab treated patients with multiple sclerosis - real life data from the Austrian MS Treatment Registry

M Guger; C Enzinger; F Leutmezer; F Di Pauli; Jörg Kraus; S Kalcher; E Kvas; T Berger

Long-term outcome and predictors of long-term disease activity in Natalizumab treated patients with multiple sclerosis - real life data from the Austrian MS Treatment Registry

M Guger
, C Enzinger
, F Leutmezer
, F Di Pauli
, Jörg Kraus
, S Kalcher
, E Kvas
, T Berger

Universitätsinstitut für Medizinisch-Chemische Labordiagnostik

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	629-630
Fachzeitschrift	MULTIPLE SCLEROSIS
Jahrgang	27
Ausgabenummer	2_SUPPL
Publikationsstatus	Veröffentlicht - 2021
Veranstaltung	37th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) - ELECTR NETWORK Dauer: 13 Okt. 2021 → 15 Okt. 2021

Dieses zitieren

Guger, M., Enzinger, C., Leutmezer, F., Di Pauli, F., Kraus, J., Kalcher, S., Kvas, E., & Berger, T. (2021). Long-term outcome and predictors of long-term disease activity in Natalizumab treated patients with multiple sclerosis - real life data from the Austrian MS Treatment Registry. MULTIPLE SCLEROSIS , 27(2_SUPPL), 629-630.

Guger, M ; Enzinger, C ; Leutmezer, F et al. / Long-term outcome and predictors of long-term disease activity in Natalizumab treated patients with multiple sclerosis - real life data from the Austrian MS Treatment Registry. in: MULTIPLE SCLEROSIS 2021 ; Jahrgang 27, Nr. 2_SUPPL. S. 629-630.

@article{70f59a995ca548a192f760e4db2a4fb9,

title = "Long-term outcome and predictors of long-term disease activity in Natalizumab treated patients with multiple sclerosis - real life data from the Austrian MS Treatment Registry",

author = "M Guger and C Enzinger and F Leutmezer and \{Di Pauli\}, F and J{\"o}rg Kraus and S Kalcher and E Kvas and T Berger",

year = "2021",

language = "English",

volume = "27",

pages = "629--630",

journal = "MULTIPLE SCLEROSIS ",

issn = "1352-4585",

publisher = "SAGE Publications",

number = "2\_SUPPL",

note = "37th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) ; Conference date: 13-10-2021 Through 15-10-2021",

}

Guger, M, Enzinger, C, Leutmezer, F, Di Pauli, F, Kraus, J, Kalcher, S, Kvas, E & Berger, T 2021, 'Long-term outcome and predictors of long-term disease activity in Natalizumab treated patients with multiple sclerosis - real life data from the Austrian MS Treatment Registry', MULTIPLE SCLEROSIS , Jg. 27, Nr. 2_SUPPL, S. 629-630.

Long-term outcome and predictors of long-term disease activity in Natalizumab treated patients with multiple sclerosis - real life data from the Austrian MS Treatment Registry. / Guger, M; Enzinger, C; Leutmezer, F et al.
in: MULTIPLE SCLEROSIS , Jahrgang 27, Nr. 2_SUPPL, 2021, S. 629-630.

Publikation: Beitrag in Fachzeitschrift › Abstrakt (Zeitschrift) › Begutachtung

TY - JOUR

T1 - Long-term outcome and predictors of long-term disease activity in Natalizumab treated patients with multiple sclerosis - real life data from the Austrian MS Treatment Registry

AU - Guger, M

AU - Enzinger, C

AU - Leutmezer, F

AU - Di Pauli, F

AU - Kraus, Jörg

AU - Kalcher, S

AU - Kvas, E

AU - Berger, T

PY - 2021

Y1 - 2021

M3 - Abstract (Journal)

SN - 1352-4585

VL - 27

SP - 629

EP - 630

JO - MULTIPLE SCLEROSIS

JF - MULTIPLE SCLEROSIS

IS - 2_SUPPL

T2 - 37th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)

Y2 - 13 October 2021 through 15 October 2021

ER -

Guger M, Enzinger C, Leutmezer F, Di Pauli F, Kraus J, Kalcher S et al. Long-term outcome and predictors of long-term disease activity in Natalizumab treated patients with multiple sclerosis - real life data from the Austrian MS Treatment Registry. MULTIPLE SCLEROSIS . 2021;27(2_SUPPL):629-630.